Biogen, Eisai move into PhIII with BACE inhibitor in Alzheimer’s – FierceBiotech

August 10, 2016 by  
Filed under Alzheimers News

Sponsored By

FierceBiotech
Biogen, Eisai move into PhIII with BACE inhibitor in Alzheimer's
FierceBiotech
Among the most advanced are Merck ($MRK), which is in Phase II/III testing for its BACE inhibitor MK-8931 in a placebo-controlled Phase II/III trial in almost 2,000 mild to moderate Alzheimer's disease patients, while partners AztraZeneca ($AZN) and
FDA Gives Green Light to Phase 3 Trials of New Alzheimer's DrugManaged Care magazine

all 3 news articles »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*